Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

TH QUARTER ENDED DECEMBER 31, 2007

Consolidated revenues were $10.2 million for the fourth quarter ended December 31, 2007 compared to $11.9 million for the same quarter in 2006. The decrease in revenues is attributable to lower sales of Impavido(R), as well as active pharmaceutical ingredients to the Company's partners, combined with lower license fees from the Company's partners.

Selling, General and Administrative (SG&A) expenses were $5.1 million for the fourth quarter ended December 31, 2007 compared to $4.2 million for the same quarter in 2006. The increase in SG&A is mainly related to the support of the continuation of a Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH) and the opening of a new operational headquarters in New Jersey.

Consolidated Research & Development (R&D) expenses were $13.6 million for the fourth quarter ended December 31, 2007 compared to $7.9 million for the same quarter in 2006. The increase in R&D expenses relates to the continuation of the Company's Phase 3 program with cetrorelix in BPH.

Consolidated net loss was $13.6 million or $0.26 per basic and diluted share for the fourth quarter ended December 31, 2007 compared to consolidated net earnings of $39.1 million or $0.74 per basic and diluted share for the same quarter in 2006. The increased net loss in the fourth quarter 2007 is related to higher loss from operations of nearly $5.2 million mainly related to increased R&D expenses, as well as to lower income tax recovery of nearly $28.4 million attributable to the recognition of future income tax assets mainly related to the sale of Atrium shares in 2006 and the special distribution of the Company's remaining interest in January 2007, combined with the decrease in net earnings from Atrium's discontinued operations of approximately $16.3 million.

The consolidated cash and short-term investments were $41.4 million as of December 31, 2007.

CONSOLIDATED RESULTS FOR THE FULL
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Grace Launches New REVELERIS® Prep Purification System 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Government ... Order and ... of,advanced technology solutions for homeland and military security, announced,today a ... of airborne biological threats. The AirSentinel,sensors, developed with support from ...
... EPI-Q, Inc., a consulting firm,providing outcomes research ... healthcare industries, announces the addition of,Anthony J. Vita, ... team of clinical,professionals. The specialized background of these ... to offer directly to those clients,seeking to enhance ...
... -,- 3Q07 Net Income Increased 58% Compared to 3Q06 to $11.9 Million, or ... ... Provides Financial Outlook for 2007 and 2008 -, NEW YORK, Nov. 5 ... of,plant-based pharmaceutical and nutraceutical products, today announced,financial results for the third quarter of ...
Cached Biology Technology:ICx Awarded Department of Defense Contract for AirSentinel Monitors 2EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8
(Date:7/30/2014)... Monash University Professor Steven Chown has been awarded ... Medal for Excellence in Antarctic Research. , SCAR, ... coordinates high quality international scientific research in the ... Antarctic region in the Earth system. The organisation ... Antarctic Treaty System, responsible for governing the region. ...
(Date:7/30/2014)... iodine-125 (125I) in cancer treatment has been shown ... are critical for neural transmission between the peripheral ... colleagues from Institute of Radiation Medicine, Chinese Academy ... be implanted into rat dorsal root ganglia (DRG) ... with different radioactivity (0, 14.8, 29.6 MBq) were ...
(Date:7/30/2014)... stem cells can develop into a multitude of cells types. ... into the specific types of mature cells that make up ... One key seems to be long chains of sugars that ... group at the University of California, San Diego, has created ... but can be more easily manipulated to direct the process, ...
Breaking Biology News(10 mins):
... Australian medical research has given pregnant women with epilepsy new ... physical birth defects. According to research published in the ... of the American Academy of Neurology, epilepsy experts at ... doses of common epilepsy drug valproate and the increased risk ...
... Medicine and Dentistry has received an award of 94,365 ... Reduction of Animals in Research (NC3Rs), for a pilot study ... cell which could be used in place of the live ... Macrophages are crucial components of the immune system and ...
... 22, 2013   Valid USA continues the expansion ... that it has acquired ScreenCheck North America (SCNA) ... the worldwide exclusive licensee for Polaroid ® identification ... to provide AAMVA compliant Real ID solutions. SCNA also ...
Cached Biology News:Epilepsy drug dosage linked to specific birth defects 2Funding for animal testing alternative 2Valid USA Continues Growth with Acquisition of ScreenCheck North America 2